Harmel Robert K, Miletic Tanja, Herzog Katja, Stechmann Bahne
EU-OPENSCREEN ERIC, Robert-Rössle-Str. 10, Building 87, 13125 Berlin, Germany.
EU-OPENSCREEN ERIC, Robert-Rössle-Str. 10, Building 87, 13125 Berlin, Germany.
SLAS Discov. 2025 Apr;32:100228. doi: 10.1016/j.slasd.2025.100228. Epub 2025 Apr 6.
EU-OPENSCREEN is the European research infrastructure consortium for chemical biology and early drug discovery. It provides open access to high-throughput screening, chemoproteomics and spatial MS-based omics platforms and medicinal chemistry groups to support the discovery of new biologically active small molecules that act as starting points for the development of new chemical tool compounds and drugs. Since its inauguration in 2018, the research infrastructure evolved from a blueprint to a fully operational platform. As new trends and technologies have an important impact on modern drug discovery, EU-OPENSCREEN continuously expands and refines its portfolio of technologies and expertise. In this perspective, the key achievements of the past six years and the planned activities over the next years are described. We illustrate how scientists can benefit from EU-OPENSCREEN through gaining access to technology platforms and expertise to unlock the extraordinary potential of their research projects and translate them into novel, impactful and innovative applications.
欧盟开放筛选计划（EU-OPENSCREEN）是欧洲化学生物学和早期药物发现研究基础设施联盟。它提供对高通量筛选、化学蛋白质组学和基于空间质谱的组学平台以及药物化学团队的开放访问，以支持发现新的生物活性小分子，这些小分子可作为开发新化学工具化合物和药物的起点。自2018年成立以来，该研究基础设施已从蓝图发展成为一个全面运营的平台。由于新趋势和技术对现代药物发现具有重要影响，欧盟开放筛选计划不断扩展和完善其技术和专业知识组合。从这个角度出发，本文描述了过去六年的关键成就以及未来几年的计划活动。我们展示了科学家如何通过使用技术平台和专业知识从欧盟开放筛选计划中受益，从而释放其研究项目的非凡潜力，并将其转化为新颖、有影响力和创新性的应用。
